Artificial Intelligence-aided diagnosis of breast cancer lymph node metastasis on histologic slides in a digital workflow
Open accessAbstract
Identifying lymph node (LN) metastasis in invasive breast carcinoma can be tedious and time-consuming. We investigated an artificial intelligence (AI) algorithm to detect LN metastasis by screening hematoxylin and eosin (H&E) slides in a clinical digital workflow. The study included 2 sentinel LN (SLN) cohorts (a validation cohort with 234 SLNs and a consensus cohort with 102 SLNs) and 1 nonsentinel LN cohort (258 LNs enriched with lobular carcinoma and postneoadjuvant therapy cases). All H&E slides were scanned into whole slide images in a clinical digital workflow, and whole slide images were automatically batch-analyzed using the Visiopharm Integrator System (VIS) metastasis AI algorithm. For the SLN validation cohort, the VIS metastasis AI algorithm detected all 46 metastases, including 19 macrometastases, 26 micrometastases, and 1 with isolated tumor cells with a sensitivity of 100%, specificity of 41.5%, positive predictive value of 29.5%, and negative predictive value (NPV) of 100%. The false positivity was caused by histiocytes (52.7%), crushed lymphocytes (18.2%), and others (29.1%), which were readily recognized during pathologists' reviews. For the SLN consensus cohort, 3 pathologists examined all VIS AI annotated H&E slides and cytokeratin immunohistochemistry slides with similar average concordance rates (99% for both modalities). However, the average time consumed by pathologists using VIS AI annotated slides was significantly less than using immunohistochemistry slides (0.6 vs 1.0 minutes, P = .0377). For the nonsentinel LN cohort, the AI algorithm detected all 81 metastases, including 23 from lobular carcinoma and 31 from postneoadjuvant chemotherapy cases, with a sensitivity of 100%, specificity of 78.5%, positive predictive value of 68.1%, and NPV of 100%. The VIS AI algorithm showed perfect sensitivity and NPV in detecting LN metastasis and less time consumed, suggesting its potential utility as a screening modality in routine clinical digital pathology workflow to improve efficiency.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Challa and colleagues evaluated the Visiopharm Integrator System metastasis AI algorithm in pathology workflows in a retrospective study at Ohio State University with promising results.
“Challa and colleagues (47) evaluated the Visiopharm Integrator System metastasis AI algorithm in pathology workflows in a retrospective study at Ohio State University with promising results.”
From Artificial Intelligence in Oncology: Current Landscape, Challenges, and Future Directions (2024) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 30 · Cited by 61
Research works printed but not linked: 1
- Ertosun MG, Rubin DL. Automated grading of gliomas using deep learning in digital pathology emages: a modular approach with ensemble of convolu- tional neural networks. AMIA Annu Symp Proc. 2015;2015:1899e1908.
- Authors
- Challa, B., Tahir, M., Hu, Y., Kellough, D., Lujan, G., Sun, S., Parwani, A. V., & Li, Z.
- Affiliations
- The Ohio State University Wexner Medical Center (US)
- Corresponding author
- Li, Zaibo
- Venue
- Modern Pathology
- Publisher
- Elsevier BV
- Published
- 2023-08
- Volume
- 36
- Issue
- 8
- Pages
- 100216
- ISSN
- 0893-3952 (ISSN-L)
- OpenAlex
- W4376130051
- Cited by
- 61
- References
- 30
- Citations by year
- 2026: 24 · 2025: 23 · 2024: 14
- FWCI
- 5.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Modern Pathology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ohio State University
- Topics
- Physical Sciences › Computer Science › Artificial Intelligence › AI in cancer detection
- Health Sciences › Medicine › Health Informatics › Artificial Intelligence in Healthcare and Education
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
- Keywords
- breast cancer, lymph node metastasis, artificial intelligence, sentinel lymph node, whole slide images, micrometastases, isolated tumor cells, cytokeratin immunohistochemistry, lobular carcinoma, histiocytes, false positives
- MeSH terms
- Artificial Intelligence, Breast Neoplasms, Female, Hematoxylin, Humans, Lymph Nodes, Lymphatic Metastasis, Carcinoma, Lobular, Sentinel Lymph Node Biopsy, Workflow
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review